Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer

BACKGROUND: CYP2D6 is a critical enzyme in the metabolism of tamoxifen and potentially a key determinant in breast cancer outcomes. Our study examined patients' beliefs about how CYP2D6 genotype would affect their prognoses. METHODS: Women enrolled in a pharmacogenomic clinical trial and on tam...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Brewer, Noel T., DeFrank, Jessica T., Chiu, Wing K., Ibrahim, Joseph G., Walko, Christine M., Rubin, Peter, Olajide, Oludamilola A., Moore, Susan G., Raab, Rachael E., Carrizosa, Daniel R., Corso, Steven W., Schwartz, Garry, Peppercorn, Jeffrey M., McLeod, Howard L., Carey, Lisa A., Irvin, William J.
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4058990/
https://ncbi.nlm.nih.gov/pubmed/24457521
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000356565
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars